Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 150 participants.
Also called NCT02449603
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 150 participants
- Sponsor
- Registry
-
NCT02449603
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02449603. Randomized; no masking; primary purpose treatment. Start 2015-11 (actual); primary completion 2018-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of Exenatide vs. Biphasic Insulin Aspart 30 on Glucose Variability in Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Exenatide
- Intervention (Drug)
- Biphasic insulin Aspart 30
- Lead sponsor
- Xijing Hospital
- Collaborator
- Air Force Military Medical University, China
- Collaborator
- First Affiliated Hospital Xi'an Jiaotong University
- Collaborator
- Second Affiliated Hospital of Xi'an Jiaotong University
- Collaborator
- Shaanxi Provincial People's Hospital
- Collaborator
- Chang'An Hospital
- Collaborator
- Xi'an Gaoxin Hospital
- Collaborator
- Xi'an Central Hospital
- Collaborator
- Shaanxi Aerospace Hospital
Record details
- Record id
cardio:ct-nct02449603- Content hash
b233a22fc6a71b7f1c6ec360e31ab546cb7c71ab93a06fbcfd888296b9ca2a62